« Back to Record
Citation APA

Majewski, I. I., Nuciforo, P., Mittempergher, L., Bosma, A. A., Eidtmann, H., Holmes, E., Sotiriou, C., Fumagalli, D., Jimenez, J., Aura, C. M., Prudkin, L., Díaz-Delgado, M. C., de la Peña, L., Loi, S., Ellis, C., Schultz, N., de Azambuja, E., Harbeck, N., Piccart-Gebhart, M., Bernards, R., & Baselga, J. (2015). PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Breast Cancer. Journal of clinical oncology. doi:10.1200/JCO.2014.55.2158


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/186678

Majewski, I. I., Nuciforo, P., Mittempergher, L., Bosma, A. A., Eidtmann, H., Holmes, E., Sotiriou, C., Fumagalli, D., Jimenez, J., Aura, C. M., Prudkin, L., Díaz-Delgado, M. C., de la Peña, L., Loi, S., Ellis, C., Schultz, N., de Azambuja, E., Harbeck, N., Piccart-Gebhart, M., Bernards, R., & Baselga, J. (2015). PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Breast Cancer. Journal of clinical oncology. doi:10.1200/JCO.2014.55.2158